我们的理念是始终如一地
纯度、品质、创新
Epax® 拥有悠久而自豪的制造历史，始终专注于追求卓越，提供安全、有效、高品质的海洋成分。我们所做的一切都基于三个核心原则：纯度、质量和创新。
Epax 品质工艺技术
近年来，我们对生产设施进行了大规模投资。我们的研发团队开发了黑箱蒸馏技术，并安装了最先进的除臭设备。
Epax 质量工艺技术 (EQP+ Tech) 使我们能够提供不仅满足而且实际上超越以下要求的产品规格：
- 欧盟和美国药典
- 食品法典标准
- GOED 专着
- IFOS 五星评级标准
新的提纯方法
EQP+ Tech 始于高品质、人类级原油。我们的专有工艺无需使用己烷、丙酮、甲醇和石油醚等溶剂或过热即可进行提纯和浓缩。然后，我们监测 22 种环境和氧化杂质。测试表明，其中 75% 的杂质一再低于领先外部实验室设定的检测限，我们甚至还测试了几个不受监管的参数。
更严格的氧化限制
氧化是油质量的重要指标。低氧化水平有助于防止自由基的形成，改善感官特性并延长保质期。我们的生产链从始至终都处于无氧环境中，并受到严格的温度控制。我们还在成品中添加天然抗氧化剂，并且每一批都经过彻底测试。
新一代工具使我们能够高精度地测量氧化过程的每个阶段，并且我们采用液相和气相色谱法来发现哪怕是微量的不良副产品。我们的氧化极限还不到 GOED 专著中规定的一半。
环境污染物的最大规格限值
氧化化合物的最大规格限值
我们所做的一切都注重质量
虽然大多数公司都在谈论质量，但 Epax® 却能保证质量。我们所做的一切都以质量为本 – 从我们使用的成分，到我们专业的产品开发和严格的制造标准。
我们已建立符合药品标准的质量体系 – 不仅适用于我们的药品系列，还适用于我们所有的产品和整个供应链。
我们所有产品的保质期至少为三年，这得益于广泛的稳定性测试程序。它们还符合世界上最严格的质量要求，包括：
- 获得 FDA 医药级批准，可用于生产医药中间体（我们是自 2012 年以来一直获得该批准的少数营养保健品供应商之一）
- 挪威药品管理局批准生产活性药物成分 (API)
- 完全符合 cGMP 标准
无忧服务
我们不仅保证产品质量，还为我们向客户提供的可靠、无忧的服务感到无比自豪。他们知道与我们合作意味着流程更简单，风险更低。
我们让您在合适的时间与拥有合适知识的合适人选轻松交谈。当然，我们许多技术娴熟、经验丰富的员工都可以通过电话和电子邮件联系，而且我们还有一支现场团队，让沟通更加顺畅。
Epax® 生态愿景
我们质量计划的一个重要组成部分是 Epax®生态愿景，即我们的环境管理政策。这是开展可持续和道德业务的三重方法：可持续、可追溯和可追溯。对您有益，对我们的地球也有益。
科学支撑创新
Epax® 是第一家根据临床研究结果开发出针对特定病症的 EPA/DHA 成分的公司。如今，研究和创新仍然是我们公司 DNA 的重要组成部分。
量研发投资让我们得以开发新产品和最先进的技术。例如，我们专有的蒸馏工艺让我们能够提供更高浓度的 EPA/DHA。
探索海洋寻找新机遇
这不仅仅是关于 Omega-3。海洋作为原料来源的全部潜力尚未被充分挖掘——而 Epax® 正处于探索这一潜力的前沿。
我们的内部研发部门拥有多项专利，并且正在酝酿令人兴奋的新概念。我们不断探索新事物，拓展我们的产品平台，并提供新的针对特定情况的配方。
与我们合作的公司将率先受益于这些新的可能性。
对科学的独特承诺
就科学证据而言，Epax® 无人能及。我们产品的安全性和有效性已在 100 多项同行评审的临床研究中得到检验 —— 比其它生成 Omega-3 公司都要多。
海洋原料行业的进一步发展取决于持续进行高质量、公正的研究。这就是为什么我们有更多的研究正在进行，以及为什么我们免费向科学家提供研究材料，没有任何附加条件。
选择 Epax®，您获得的不仅仅是安全、纯净的成分。您可以确信，您正在与一位真正致力于科学研究的合作伙伴合作。
科研成果
- von Schacky C, Angerer P, Kothny W. Et al. The effect of dietary omega-3 fatty acids on coronary atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann.Intern.Med. 1999;130:554-562
- von Schacky C, Baumann K, Angerer P. The effect of n-3 fatty acids on coronary atherosclerosis: results from SCIMO, an angiographic study, background and implications.LIPIDS 2001;36:S99-S102
- Lervang HH, Schmidt EB, Møller JM. Et al. The effect of low-dose supplementation with n-3 polyunsaturated fatty acids on some risk markers of coronary heart disease. Scand J Clin Lab Invest 1993;53:417-423
- Markmann P, Lerche C, Nørtoft LL. A critical view on using fish-oil in prevention of ischaemical heart disease. Ugeskr Laeger 1992;154:2288-2292
- Schmidt EB. n-3 fatty acids and the risk of coronary heart disease. Dan.Med.Bull 1997;44:1-22
- Marckmann P, Bladbjerg EM, Jespersen J et al. Dietary fish oil (4 g daily) and cardiovascular risk markers in healthy men. Arterioscler.Thromb.Vasc.Biol. 1997;17:3384-3391
- Rees D, Miles EA, Banerjee T, et al. Dose-related effects of eicosapentaenoic acid on innate immune function in healthy humans: a comparison of young and older men. American.journal of clinical.nutrition 2006;83:331-342
- Cazzola R, Russo-Volpe S, Miles EA, et al. Age- and dose-dependent effects of an eicosapentaenoic acid-rich oil on cardiovascular risk factors in healthy male subjects. Atherosclerosis 2007;193:159-167
- Einvik G, Klemsdal TO, Sandvik L et al. A randomized clinical trial on n-3 PUFA supplementation and all-cause mortality in elderly men at high cardiovascular risk. Eur J Cardiovasc Rehab 2010;17:588-592
- Hjerkinn EM, Abdelnoor M, Breivik L et al. Effect of diet or very long chain omega-3 fatty acids on progression of atherosclerosis, evaluated by carotid plaques, intima-media thickness and by pulse wave propagation in elderly men with hypercholesterolaemia. European Journal of Cardiovascular Prevention and Rehabilitation 2006;13:325-333
- Dyerberg J, Eskesen DC, Andersen PW et al. Effects of trans- and n-3 unsaturated fatty acids on cardiovascular risk markers in healthy males. European.journal of clinical.nutrition 2004;58:1062-1070
- Dyerberg J, Christensen JH, Eskesen D et al. Trans, and n-3 polyunsaturated fatty acids and vascular function-A yin yang situation. Atherosclerosis.Supplements 2006;33-35
- Schmidt EB, Varming K, Pedersen JO et al. Long-term supplementation with n-3 fatty acids. Scan J Clin Lab Invest 1992;52:229-236
- Wu S-Y, Mayneris-Perxachs J, Lovegrove JA, Todd S, and Yaqoob P. Fish-oil supplementation alters numbers of circulating endothelial progenitor cells and microparticles independent of eNOS genotype. AJCN 2014 doi: 10.3945/ajcn.114.088880.
- Minihane AM, Khan S, Leigh-Firbank EC et al. ApoE polymorphism and fish oil supplementation in subjects with an atherogenic lipoprotein phenotype. Atheriosclerosis, thrombosis, and vascular biology 2000;20:1990-1997
- Nordøy A, Hatcher LF, Ullman DL et al. Individual effects of dietary saturated fatty acids and fish oil on plasma lipids and lipoproteins in men. Am J Clin Nutr 1993;57:634-639
- Schmidt EB, Ernst E, Varming K et al. The effect of n-3 fatty acids on lipids and haemostasis in patients with Type IIa and Type IV hyperlipidemia. Thromb Haemostas 1989;62:797-801
- Schmidt EB, Sørensen PJ, Pedersen JO et al. The effect of n-3 polyunsaturated fatty acids on lipids, haemostasis, neutrophil and monocyte chemotaxis in insulin-dependant diabetes mellitus. J Intern Med 1989;225 (suppl):201-206
- Schmidt EB, Varming K, Ernst E et al. Dose-response studies on the effect of n-3 polyunsaturated fatty acids on lipids and haemostasis. Tromb Haemostas 1990;63:1-5
- Schmidt EB, Pedersen JO, Varming K et al. N-3 fatty acids and leucocyte chemotaxis. Effects in hyperlipidaemia and dose-response studies in healthy men. Arterosclerosis and Thrombosis 1991;11:429-435
- Schmidt EB, Klausen IC, Kristensen SD et al. The effect of n-3 polyunsaturated fatty acids on Lp(a). Clin Chim Acta 1991;198:271-278
- Schmidt EB, Varming K, Svaneborg N et al. N-3 polyunsaturated fatty acid supplementation in men with moderate and severe hypertriglyceridemia: a dose-response study. Ann Nutr Metab 1992;36:283-287
- Schmidt EB, Lervang HH, Varming K et al. Long-term supplementation with n-3 fatty acids: effects on blood lipids, haemostasis and blood pressure. Scand J Clin Lab Invest 1992;52:221-228
- Svaneborg N, Møller JM, Schmidt EB et al. The acute effects of a single very high dose of n-3 fatty acids on plasma lipids and lipoproteins in healthy subjects. Lipids 1994;29:145-147
- Stark KD, Park EJ, Maines VA et al. Effect of a fish-oil concentrate on serum lipids in postmenopausal women receiving and not receiving hormone replacement therapy. Am J Clin Nutr 2000;72:389-394
- Seljeflot I, Johansen O, Arnesen H et al. Procoagulant activity and cytokine expression in whole blood cultures from patients with atherosclerosis supplemented with omega-3 fatty acids. Thromb.Haemost. 1999;81:566-570
- Lindman AS, Pedersen JI, Hjerkinn EM et al. The effects of long-term diet and omega-3 fatty acid supplementation on coagulation factor VII and serum phospholipids with special emphasis on the R353Q polymorphism of the FVII gene. Thrombosis.and haemostasis 2004;6:1097-1104
- Barstad RM, Roald HE, Petersen LB et al. Dietary supplementation of omega-3 fatty acids has no effect on acute collagen induced thrombus formation in flowing native blood. Blood Coagul Fibrinolysis. 1995;6:374-381
- Flaten H, Høstmark AT, Kierulf P et al. Fish-oil concentrate: effects on variables related to cardiovascular disease. Am J Clin Nutr 1990;52:300-306
- Freese R, Mutanen M. Alpha-linolenic acid and marine long-chain n-3 fatty acids only slightly differ in their effects on haemostatic factors in healthy subjects. Am J Clin Nutr 1997;66:591-598
- Freese R, Mutanen M. Small effects of linseed oil or fish oil supplementation on postprandial changes in hemostatic factors. Thromb Res 1997;85(2):147152
- Freese R. Dietary fatty acids and hemostasis. Effects of n-3 and n-6 fatty acids on platelet function and coagulation in healthy subjects. 1997;Uni Helsinki 75
- Müllertz A, Hølmer G, Grøndahl-Hansen J et al. Increased concentration of plasminogen activator inhibitor type-1 in plasma after intake of fish oil. Fibrinolysis 1990;4(suppl 2):86-88
- Christensen JH, Gustenhoff P, Korup E et al. n-3 polyunsaturated fatty acids, heart rate variability and ventricular arrhythmias in post-AMI-patients. A clinical controlled trial. Ugeskr.Laeger 1997;159:5526-5529
- Christensen JH, Gustenhoff P, Korup E et al. Effect of fish oil on heart rate variability in survivors of myocardial infarction: a double blind randomised controlled trial. BMJ 1996;312:677-678
- Christensen JH, Gustenhoff P, Ejlersen E et al. n-3 fatty acids and ventricular extrasystoles in patients with ventricular tachyarrhythmias. Nutrition Res 1995;15:1-8
- Christensen JH, Gustenhoff P, Korup E et al. n-3 fatty acids and ventricular arrhythmias in post-myocardial infarction patients with a low ejection fraction 1995;10:107-114
- Christensen JH, Christensen MS, Dyerberg J et al. Heart rate variability and fatty acid content of blood cell membranes: a dose-response study with n-3 fatty acids. Am J Clin Nutr 1999;70:331-337
- Christensen JH, Aarøe J, Knudsen N et al. Heart rate variability and n-3 fatty acids in patients with chronic renal failure. Clin Neprol 1998;49:102-106
- Kumar S, Sutherland F, Wheeler M, Heck PM, Lee G, Teh AW, Manohar LG, Morgan JG, Sparks PB. Effects of chronic omega-3 polyunsaturated fatty acid supplementation on human atrial mechanical function after reversion of atrial arrhythmias to sinus rhythm: Reversal of tachycardia-mediated atrial cardiomyopathy with fish oils. Heart Rhythm 2011;8:643-649
- Seljeflot I, Arnesen H, Brude IR et al. Effects of omega-3 fatty acids and/or antioxidants on endothelial cell markers. Eur.J.Clin.Invest. 1998;28:629-635
- Berstad P, Seljeflot I, Veierod MB et al. Supplementation with fish oil affects the association between very long-chain n-3 polyunsaturated fatty acids in serum non-esterified fatty acids and soluble vascular cell adhesion molecule-1. Clinical.science 2003;105:13-20
- Eid H, Arnesen H, Hjerkinn EM et al. Effect of diet and omega-3 fatty acid intervention on asymmetric dimethylarginine. Nutrition & Metabolism 2006;3:4
- Furenes EB, Seljeflot I, Solheim S et al. Long-term influence of diet and/or omega-3 fatty acids on matrix metalloproteinase-9 and PAPP-A in men at high risk of coronary heart disease. SCLI 2008;68:177-184
- Bonnema SJ, Jespersen LT, Marving J et al. Supplementation with olive oil rather than fish oil increases small arterial compliance in diabetic patients Diab Nutr & Metabol 1995;8:81-87
- Hjerkinn EM, Seljeflot I, Ellingsen I et al. Influence of long-term intervention with dietary counseling, long-chain n-3 fatty acid supplements, or both on circulating markers of endothelial activation in men with long-standing hyperlipidemia. American.journal of clinical.nutrition 2005;81:583-589
- Christensen JH, Therkelsen K, Møller JM et al. n-3 fatty acids do not decrease plasma endothelin levels in healthy individuals. Scan J Clin Invest 1997;57:495-500
- Fashing P, Ratheiser K, Waldhäusl W et al. Metabolic effects of fish-oil supplementation in patients with impaired glucose tolerance. Diabetes 1991;40:583-589
- Fashing P, Rohac M, Liener K et al. Fish oil supplementation versus gemfibrozil treatment in hyperlipidemic NIDDM. Horm Metab Res 1996;28:230-236
- Troseid M, Seljeflot I, Hjerkinn EM et al. Il-18 is a strong predictor of cardiovascular events in elderly men with the metabolic syndrome. Diab Care 2008;32:486-492
- Kamolrat T, Gray SR, and Thivierge MC. Fish oil positively regulates anabolic signalling alongside an increase in whole-body gluconeogenesis in ageing skeletal muscle. Eur J Nutr 2013;52(2):647-657
- Flachs P, Rossmeisl M, and Kopecky J. The effect of n-3 fatty acids on glucose homeostasis and insulin sensitivity. Physiol Res 2014;63(1): 93-118
- Kopecky J, et al. Combined intervention with Pioglitazone and n-3 fatty acids in metformin-treated diabetic patients on postprandial lipid clearance and selected cytokines. Nutrition & Metabolism NUAM-D-15-00080R1
- Razny,U., Kiec-Wilk,B., Polus,A., Goralska,J., Malczewska-Malec,M., Wnek,D., Zdzienicka,A., Gruca,A., Childs,C.E., Kapusta,M., Slowinska-Solnica,K., Calder,P.C., and Dembinska-Kiec,A. (2015) Effect of caloric restriction with or without n-3 polyunsaturated fatty acids on insulin sensitivity in obese subjects: A randomized placebo controlled trial, BBA clinical 4, 7-13.
- Bas JM, Caimari A, Rodriguez-Naranjo MI, Childs CE, Chavez CP, West AL, Miles EA, Arola L, Calder PC. Impairment of lysophospholipid metabolism in obesity: altered plasma profile and desensitization to the modulatory properties of n–3 polyunsaturated fatty acids in a randomized controlled trial. Am J Clin Nutr 2016;104:266-279
- Razny Urszula, Beata Kiec-Wilk, Anna Polus, Joanna Goralska, Malgorzata Malczewska-Malec, Dominika Wnek, Anna Zdzienicka et al. 2015. Effect of caloric restriction with or without n-3 polyunsaturated fatty acids on insulin sensitivity in obese subjects: a randomized placebo controlled trial. BBA Clinical 2015;4:7–13
- Clark,L.F., Thivierge,M.C., Kidd,C.A., McGeoch,S.C., Abraham,P., Pearson,D.W.M., Horgan,G.W., Holtrop,G., Thies,F., and Lobley,G.E. (2016) Fish oil supplemented for 9 months does not improve glycaemic control or insulin sensitivity in subjects with impaired glucose regulation: a parallel randomised controlled trial, The British journal of nutrition 115, 75-86
- Polus A, Zapala B, Razny U, Gielicz A, Kiec-Wilk B, Malczewska-Malec M, Sanak M, Childs CE, Calder PC, Dembinska-Kiec A. Omega-3 fatty acid supplementation influences the whole blood transcriptome in women with obesity, associated with pro-resolving lipid mediator production. Biochim Biophys Acta. 2016;1861(11):1746-1755
- Rohith N. Thota, Shamasunder H. Acharya and Manohar L. Garg. Curcumin and/or omega-3 polyunsaturated fatty acids supplementation reduces insulin resistance and blood lipids in individuals with high risk of type 2 diabetes: a randomised controlled trial, Thota et al. Lipids in Health and Disease (2019) 18:31 https://doi.org/10.1186/s12944-019-0967-x
- Espersen GT, Grunnet N, Lervang HH et al. Decreased interleukin-1 beta levels in plasma from rheumatoid arthritis patients after dietary supplementation with n-3 polyunsaturated fatty acids. Clin Rheum 1992;11(3):393-395
- Faarvang KL, Nielsen, Thomsen BS et al. Fish oil and rheumatoid arthritis: a randomised double-blind study. Ugeskrift Laeger 1994;156:3495-3498
- Hansen GVO, Nielsen L, Kluger E et al. Nutritional status of Danish rheumatoid patients and effects of a diet adjusted in energy intake, fish-oil and antioxidants. Scand J Rheumatol 1996;25:325-330
- Nielsen GL, Faarvang BS, Thomsen BS et al. The effects of dietary supplementation with n-3 polyunsaturated fatty acids in patients with rheumatoid arthritis. Eur J Clin Invest 1992;22:687-691
- Volker DH, Fitzgerald P, Major G et al. Efficacy of a fish-oil concentrate in the treatment of rheumatoid arthritis. J Rheumatol 2000;27:2343-2346
- Sundstrom B, Stalnacke K, Hagfors L et al. Supplementation of omega-3 fatty acids in patients with ankylosing spondylitis. Scandinavian journal of rheumatology. 2006;39:359-362
- Freund-Levi Y, Eriksdotter-Jonhagen M, Cederholm T et al. Omega-3 Fatty Acid Treatment in 174 Patients With Mild to Moderate Alzheimer Disease: OmegAD Study: A Randomized Double-blind Trial. Archives of neurology 2006;63:1402-1408
- Freund-Levi Y, Basun H, Cederholm T et al. Omega-3 supplementation in mild to moderate Alzheimer’s disease: effects on neuropsychiatric symptoms. Internat J Geriatric Psych 2008;23(2):161-169
- Faxen-Irving G, Freund-Levi Y, Eriksdotter Jonhagen M, et al. N-3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer’s disease. Journal Am Geriatric Soc 2009;57:11-17
- Vedin I, Cederholm T, Freund Levi Y, et al. Effects of docosahexaenoic acid–rich n3 fatty acid supplementation on cytokine release from blood mononuclear leukocytes: the OmegAD study. Am J Clin Nutr 2008;87:1616 –22
- Lai KL, Shahar S, Chin AV, et al. Docosahexaenoic acid-concentrated fish oil supplementation in subjects with mild cognitive impairment (MCI): a 12-month randomised, double-blind, placebo-controlled trial. Psychopharmacology 2013;225:605–612
- Lai KL, Shahar S; Rajab N, et al. The role of long chain omega-3 polyunsaturated fatty acids in reducing lipid peroxidation among elderly patients with mild cognitive impairment: a case-control study. Journal of nutritional biochemistry 2013; 24 (5):803-808
- Faxen-Irving G, Freund-Levi Y, Eriksdotter-Jonhagen M, et al. Effects on Transthyretin in Plasma and Cerebrospinal Fluid by DHA-Rich n – 3 Fatty Acid Supplementation in Patients with Alzheimer’s Disease: The OmegAD Study. Journal of Alzheimer’s disease 2013;36(1):1 – 6
- Nolan, J. M., Mulcahy, R., Power, R., Moran, R., & Howard, A. N. (2018). Nutritional Intervention to Prevent Alzheimer’s Disease: Potential Benefits of Xanthophyll Carotenoids and Omega-3 Fatty Acids Combined. J Alzheimers Dis, 64(2), 367-378. doi:10.3233/jad-180160
- Olsen SF, Sørensen JD, Secher NJ et al. A randomised controlled trial of effect of fish-oil supplementation on pregnancy duration. Lancet 1992;339:1003-1007
- Olsen SF, Sørensen JD, Secher NJ et al. Fish-oil supplementation and pregnancy duration: a randomised controlled trial. Ugeskr Laeger 1994;156:1302-1307
- Olsen SF, Secher NJ, Tabor A et al. Randomised clinical trial of fish oil supplementation in high risk pregnancies. Brit J Obstet Gynecol 2000;107:382-395
- Salvig JD, Olsen SF, Secher NJ. Effects of fish oil supplementation in late pregnancy on blood pressure: a randomised controlled trial. Brit J Obstet Gynecol 1996;103:529-533
- Sørensen JD, Olsen SF, Pedersen AK et al. Effects of fish oil supplementation in the third trimester of pregnancy on prostacyclin and thromboxane production. Am J Obstet Gynecol 1993;168:915-922
- Sørensen JD, Olsen SF, Secher NJ et al. Effects of fish oil supplementation in late pregnancy on blood lipids, serum urate, coagulation and fibrinolysis: a randomised controlled study. Fibrinolysis 1994;8:54-60
- Vanhouwelingen AC, Sørensen JD, Hornstra G et al. Essential fatty acid status in neonates after fish-oil supplementation during late pregnancy Br J Nutr 1995;74:723-731
- Olsen SF, Osterdal ML, Salvig JD et al Duration of pregnancy in relation to fish oil supplementation and habitual fish intake: a randomised clinical trial with fish oil. European journal of clinical nutrition; 2007;61(8): 976-85
- Freeman MP, Hibbeln JR, Wisner KL et al. Randomized dose-ranging pilot trial of omega-3 fatty acids for postpartum depression. Acta psychiatrica Scandinavica 2006;113:31-35
- Klingler M, Blaschitz A, Campoy C et al. The effect of docosahexaenoic acid and folic acid supplementation on placental apoptosis and proliferation. British Journal of Nutrition 2006;96:182-190
- Barque E, Krauss-Etschmann S, Campoy C et al. Docosahexaenoic acid supply in pregnancy affects placental expression of fatty acid transport proteins. American Journal of Clinical Nutrition 2006;84:853-861
- Shoji H, Franke C, Campoy C et al. Effect of docosahexaenoic acid and eicosapentaenoic acid supplementation on oxidative stress levels during pregnancy. Free Radical Research 2006;40:379-384
- Mølvig J, Pociot F, Worsaae H et al. Dietary supplementation with n-3 polyunsaturated fatty acids decreases mononuclear cell proliferation and interleukin-beta content but not monokine secretion in healthy and insulin-dependent diabetic individuals. Scand J Immunol 1991;34:399-410
- Schmidt EB, Varming K, Møller JM et al. No effect of a very low dose of n-3 fatty acids on monocyte function in healthy humans. Scan J Lab Invest 1996;56:87-92
- Toft AD, Thorn M, Ostrowski K et al. N-3 polyunsaturated fatty acids do not affect cytokine response to strenous exercise. J Appl Physiol 2000;89:2401-2406
- Varming K, Schmidt EB, Svaneborg N et al. The effect of n-3 fatty acids on neutrophil chemiluminiscience. Scand J Clin Lab Invest 1995;55:47-52
- Rees D, Miles EA, Banerjee T et al. Dose-related effects of eicosapentaenoic acid on innate immune function in healthy humans: a comparison of young and older men. Am J Clin Nutr 2006;83:331-342
- Josep M del Bas, Antoni Caimari, Maria Isabel Rodriguez-Naranjo et al. Impairment of lysophospholipid metabolism in obesity: altered plasma profile and desensitization to the modulatory properties of n–3 polyunsaturated fatty acids in a randomized controlled trial. Am J Clin Nutr 2016;104:266–79
- Williams EJ, Baines KJ, Smart JM, Gibson PG, Wood LG. Rosuvastatin, Lycopene and Omega-3 fatty acids: A potential treatment for systemic inflammation in COPD; a pilot study. J of Nutr & Intermediary Metabolism. 2016;5:86-95
- Schmidt EB, Moller JM, Svaneborg N et al. Safety aspects of fish oils: experience with an n-3 concentrate of reesterified triglycerides. Drug Invest 1994;7:215-220
- Schmidt EB, Moller JM, Svaneborg N et al. Prevention and treatment of vascular disease. Safety aspects of dietary n-3 fatty acids. Springer Verlag 1995;18:195-206
- Bioavailability: Dyerberg J, Madsen P, Møller JM et al. N-3 fatty acids in prevention and treatment in vascular disease. Springer Verlag 1995;20:201-217
- Bioavailability: Nordøy A, Barstad L, Connor WE et al. Absorption of the n-3 eicosapentaenoic and docosahexaenoic acids as ethyl esters and triglycerides by humans. Am J Clin Nutr 1991;53:1185-1190
- Bioavailability: Dyerberg J, Madsen P, Møller JM. Bioavailability of n-3 fatty acid formulations. Springer Verlag 1995;20:217-226
- Transplantation: Hansen JM, Løkkegaard H, Hoy CE et al. No effect of dietary fish oil on renal hemodynamics, tubular function, and renal function reserve in long-term renal transplant recipients. J Am Soc Nephrol 1995;5:1434-1440
- Transplantation: Hansen JM, Hoy CE, Strandgaard. Fish oil and cyclosporin A induced renal hypoperfusion in kidney-transplanted patients. Nephrology Dialysis Transplantation 1995;10:1745-1750
- Physical performance: Raastad T, Høstmark AT, Strømme SB. Omega-3 fatty acid supplementation does not improve maximal aerobic power, anaerobic threshold and running performance in well-trained soccer players. Scand J Med Sci Sports 1997;7:25-31
- Digestion: Riber C, Højgaard L, Madsen JL et al. Gallbladder emptying and cholecystokinin response to fish oil and trioleate ingestion. Digestion 1996;57(3):161-164
- Weight reduction: Kunnesova M, Srbova L, Hlavaty P et al. Praha omega-3 weight reduction study. ECO 2008; abstract
- Infection: Abu-Zeid YA, Hansen HS, Jakobsen PH et al. No effect of human serum and erythrocytes enriched in n-3 fatty acids by oral intake on plasmodium falciparum bloodstage parasites in vitro. Eur J Clin Nutr 1993;47:431-436
- Depression: Voggt A, Berger M, Obermeier M, Löw A, Seemueller F, Riedel M, Moeller HJ, Zimmermann R, Kirchberg F, Von Schacky C, Severus E. Heart rate variability and Omega-3 Index in euthymic patients with bipolar disorders. Eur Psychiatry 2015:30(2):228-232
- Depression: Parletta N, Zarnowiecki D, Cho J, Wilson A, Bogomolova S, Villani A. A Mediterranean-style dietary intervention supplemented with fish oil improves diet quality and mental health in people with depression: A randomized controlled trial (HELFIMED). Nutritional Neuroscience 2017;1411320
- Analysis: Sjövall,P., Rossmeisl,M., Hanrieder,J., Kuda,O., Kopecky,J., and Bryhn,M. Dietary uptake of omega-3 fatty acids in mouse tissue studied by time-of-flight secondary ion mass spectrometry (TOF-SIMS), Analytical and bioanalytical chemistry 2015;407:5101-5111.
- Psychotic Disorders: McGorry PD, Nelson B, Markulev C. Effect of ω-3 Polyunsaturated Fatty Acids in Young People at Ultrahigh Risk for Psychotic Disorders; The NEURAPRO Randomized Clinical Trial. JAMA Psychiatry 2017;74(1):19-27
- Psychotic Disorders: Amminger GP, Schafer MR, Schlogelhofer M, Clier CM, McGorry PD. Longer-term outcome in the prevention of psychotic disorders by the Vienna Omega-3 study. Nature communications 2015;6:7934
- Eye Health: McDonald MB, Sheha H, Tighe S, Janik SB, Bowden FW, Chokshi AR, Singer MA, Nanda S, Qazi MA, Dierker D, Shupe AT, McMurren BJ. Treatment outcomes in the DRy Eye Amniotic Membrane (DREAM) study. Clin Ophthalmol. 2018 Apr 9;12:677-681
- Metabolic Syndrome: Abbott, K., Burrows, T. L., Acharya, S., Thota, R. N., & Garg, M. L. (2020). Dietary supplementation with docosahexaenoic acid rich fish oil increases circulating levels of testosterone in overweight and obese men. Prostaglandins Leukot Essent Fatty Acids, 163, 102204. doi:10.1016/j.plefa.2020.102204
- Metabolic Syndrome: Abbott, K. A., Burrows, T. L., Acharya, S., Thota, R. N., & Garg, M. L. (2020). DHA-enriched fish oil reduces insulin resistance in overweight and obese adults. Prostaglandins Leukot Essent Fatty Acids, 159, 102154. doi:10.1016/j.plefa.2020.102154
- Metabolic Syndrome: Thota, R. N., Acharya, S. H., & Garg, M. L. (2019). Curcumin and/or omega-3 polyunsaturated fatty acids supplementation reduces insulin resistance and blood lipids in individuals with high risk of type 2 diabetes: a randomised controlled trial. Lipids Health Dis, 18(1), 31. doi:10.1186/s12944-019-0967-x
- Metabolic Syndrome: Thota, R. N., Rosato, J. I., Burrows, T. L., Dias, C. B., Abbott, K. A., Martins, R. N., & Garg, M. L. (2020). Docosahexaenoic Acid-Rich Fish Oil Supplementation Reduces Kinase Associated with Insulin Resistance in Overweight and Obese Midlife Adults. Nutrients, 12(6). doi:10.3390/nu12061612